Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer's Disease: Timing and Duration of Adverse Events - PubMed
3 hours ago
- #Agitation Safety
- #Alzheimer's Disease
- #Brexpiprazole
- Brexpiprazole, an atypical antipsychotic, is evaluated for safety in treating agitation in Alzheimer's dementia through post hoc analyses of clinical trials.
- Over 12 weeks, brexpiprazole (2 or 3 mg/day) showed similar time to first treatment-emergent adverse event (TEAE) and duration of TEAEs compared to placebo, with a longer time to discontinuation due to adverse events.
- Over 24 weeks, brexpiprazole demonstrated a median time to first TEAE of 52 days and a median duration of TEAEs of 3 days, indicating good tolerance among patients who tolerated the initial 12 weeks.
- The analysis reinforces that brexpiprazole is generally well tolerated for up to 24 weeks, providing practical clinical insights into its safety profile for agitation in Alzheimer's disease.
- Adverse events with brexpiprazole, such as stroke, heart failure, restlessness, dizziness, falls, sleepiness, and drowsiness, were rare and comparable to placebo in timing and duration.